Literature DB >> 23474162

The effect of a therapy protocol for increasing correction of severely contracted proximal interphalangeal joints caused by dupuytren disease and treated with collagenase injection.

Terri M Skirven1, Abdo Bachoura, Sidney M Jacoby, Randall W Culp, A Lee Osterman.   

Abstract

PURPOSE: To determine the effect of a specific orthotic intervention and therapy protocol on proximal interphalangeal (PIP) joint contractures of greater than 40° caused by Dupuytren disease and treated with collagenase injections.
METHODS: All patients with PIP joints contracted at least 40° by Dupuytren disease were prospectively invited to participate in the study. Following standard collagenase injection and cord rupture by a hand surgeon, a certified hand therapist evaluated and treated each patient based on a defined treatment protocol that consisted of orthotic intervention to address residual PIP joint contracture. In addition, exercises were initiated emphasizing reverse blocking for PIP joint extension and distal interphalangeal joint flexion exercises with the PIP joint held in extension to lengthen a frequently shortened oblique retinacular ligament. Patients were assessed before injection, immediately after injection, and 1 and 4 weeks later. There were 22 fingers in 21 patients. The mean age at treatment was 63 years (range, 37-80 y).
RESULTS: The mean baseline passive PIP joint contracture was 56° (range, 40° to 80°). At cord rupture, the mean PIP joint contracture became 22° (range, 0° to 55°). One week after cord rupture and therapy, the contracture decreased further to a mean of 12° (range, 0° to 36°). By 4 weeks, the mean contracture was 7° (range, 0° to 35°). The differences in PIP joint contracture were statistically significant at all time points except when comparing the means at 1 week and 4 weeks. The results represent an 88% improvement of the PIP joint contracture.
CONCLUSIONS: In the short term, it appears that severe PIP joint contractures benefit from specific, postinjection orthotic intervention and targeted exercises. TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic IV.
Copyright © 2013 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23474162     DOI: 10.1016/j.jhsa.2013.01.038

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  10 in total

1.  Clinical outcomes following collagenase injections compared to fasciectomy in the treatment of Dupuytren's contracture.

Authors:  Raghuveer C Muppavarapu; Michael J Waters; Matthew I Leibman; Mark R Belsky; David E Ruchelsman
Journal:  Hand (N Y)       Date:  2015-06

Review 2.  Collagenase Treatment in Dupuytren Contractures: A Review of the Current State Versus Future Needs.

Authors:  Ilse Degreef
Journal:  Rheumatol Ther       Date:  2016-02-03

Review 3.  Collagenase clostridium histolyticum in Dupuytren's contracture: a systematic review.

Authors:  Francesco Smeraglia; Angelo Del Buono; Nicola Maffulli
Journal:  Br Med Bull       Date:  2016-05-05       Impact factor: 4.291

4.  Examining the efficacy and maintenance of contracture correction after collagenase clostridium histolyticum treatment for Dupuytren's disease.

Authors:  Heather A McMahon; Abdo Bachoura; Sidney M Jacoby; David S Zelouf; Randall W Culp; A Lee Osterman
Journal:  Hand (N Y)       Date:  2013-09

5.  Early results of the use of collagenase in the treatment of Dupuytren's contracture.

Authors:  S Considine; R Heaney; K M Hirpara
Journal:  Ir J Med Sci       Date:  2014-04-06       Impact factor: 1.568

6.  Collagenase treatment of Dupuytren's contracture using a modified injection method: a prospective cohort study of skin tears in 164 hands, including short-term outcome.

Authors:  Isam Atroshi; Jesper Nordenskjöld; Anna Lauritzson; Eva Ahlgren; Johanna Waldau; Markus Waldén
Journal:  Acta Orthop       Date:  2015-02-19       Impact factor: 3.717

Review 7.  Postapproval clinical experience in the treatment of Dupuytren's contracture with collagenase clostridium histolyticum (CCH): the first 1,000 days.

Authors:  Scott M Schulze; James P Tursi
Journal:  Hand (N Y)       Date:  2014-12

Review 8.  What are we measuring? A critique of range of motion methods currently in use for Dupuytren's disease and recommendations for practice.

Authors:  Anna L Pratt; Catherine Ball
Journal:  BMC Musculoskelet Disord       Date:  2016-01-13       Impact factor: 2.362

9.  Costs for collagenase injections compared with fasciectomy in the treatment of Dupuytren's contracture: a retrospective cohort study.

Authors:  Isam Atroshi; Emelie Strandberg; Anna Lauritzson; Eva Ahlgren; Markus Waldén
Journal:  BMJ Open       Date:  2014-01-15       Impact factor: 2.692

10.  A Personalized Approach to Treat Advanced Stage Severely Contracted Joints in Dupuytren's Disease with a Unique Skeletal Distraction Device-Utilizing Modern Imaging Tools to Enhance Safety for the Patient.

Authors:  Wibke Müller-Seubert; Aijia Cai; Andreas Arkudas; Ingo Ludolph; Niklas Fritz; Raymund E Horch
Journal:  J Pers Med       Date:  2022-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.